Erratum: Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome (Case Reports in Immunology (2019) 2019 (5) DOI: 10.1155/2019/6357256)

In the article titled "Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome"[1], authors Mario Alberto Ynga-Durand and Julio César Alcántara-Montiel were affiliated to "Universidad Nacional Autónoma de Mexico, Facultad de Estudios Superiores Zaragoza, Facultad de Medicina, Mexico,"which is incorrect. The correct affiliation of Mario Alberto Ynga-Durand is "Laboratorio de Inmunidad de Mucosas, Sección de Investigación y Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico."The correct affiliation for Julio César Alcántara-Montiel is "Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico."The error was introduced during the production process of the article, and Hindawi apologises for causing this error in the article. The corrected list of affiliations is shown in the authors' information above.